Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28598116 | 0.94 | ALDH1A1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL11083028 | 0.87 | MEN1 (0.43) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL23544814 | 0.84 | MEN1 (0.46) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL8268349 | 0.81 | NPC1 (0.43) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6714850 | 0.80 | MEN1 (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL13455405 | 0.80 | MEN1 (0.44) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL11024894 | 0.80 | MEN1 (0.54) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL12025010 | 0.79 | MEN1 (0.41) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL20090415 | 0.79 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL22633349 | 0.79 | MEN1 (0.43) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150232616-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-8980326-B2 | Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents | INTEZYNE TECHNOLOGIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8779008-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140170225-A1 | IMMUNOTHERAPY FOR TREATMENT OF AMYLOID-RELATED DISORDERS USING ENCAPSULATED BETA-AMYLOID PEPTIDES | INTEZYNE TECHNOLOGIES INC (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-11-14 | — | — | US | disclosed |
| US-7638558-B2 | drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7618944-B2 | Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7612153-B2 | conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612153-B2 | conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7601796-B2 | polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601796-B2 | polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | IAPP, APP, TTR | MEN1 227/4885KMT2A 4844/4885KDM4C 4846/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MEN1 1452/4885KMT2A 1133/4885KDM4C 3360/4885 |
| US-20130303534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MEN1 1452/4885KMT2A 1133/4885KDM4C 3360/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MEN1 1452/4885KMT2A 1133/4885KDM4C 3360/4885 |
| US-20140170225-A1 | IMMUNOTHERAPY FOR TREATMENT OF AMYLOID-RELATED DISORDERS USING ENCAPSULATED BETA-AMYLOID PEPTIDES | IAPP, APP, TTR | MEN1 271/4885KMT2A 3377/4885KDM4C 4463/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | MEN1 1452/4885KMT2A 1133/4885KDM4C 3360/4885 |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | LIPA, LPXN, CD47 | MEN1 161/4885KMT2A 4044/4885KDM4C 3322/4885 |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | CLTB, SLC1A5, CLTA | MEN1 2136/4885KMT2A 1428/4885KDM4C 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.